Rxivist logo

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

By Mark J Mulligan, Kirsten E. Lyke, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen P. Lockhart, Kathleen M Neuzil, Vanessa N Raabe, Ruth Bailey, Kena A. Swanson, Ping Li, Kenneth Koury, Warren Kalina, David Cooper, Camila Fonter-Garfias, Pei-Yong Shi, Ozlem Tuereci, Kristin R. Tompkins, Edward E. Walsh, Robert Frenck, Ann R Falsey, Philip R. Dormitzer, William C. Gruber, Ugur Sahin, Kathrin U. Jansen

Posted 01 Jul 2020
medRxiv DOI: 10.1101/2020.06.30.20142570

Abstract In March 2020, the WHO declared a pandemic of coronavirus disease 2019 (COVID-19), due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With >8.8 million cases and >450,000 deaths reported globally, a vaccine is urgently needed. We report the available safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among healthy adults, 18-55 years of age, randomized to receive 2 doses, separated by 21 days, of 10 g, 30 g, or 100 g of BNT162b1, a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers in sera increased with dose level and after a second dose. Geometric mean neutralizing titers reached 1.8- to 2.8-fold that of a panel of COVID-19 convalescent human sera. These results support further evaluation of this mRNA vaccine candidate.

Download data

  • Downloaded 74,118 times
  • Download rankings, all-time:
    • Site-wide: 116
    • In infectious diseases: 46
  • Year to date:
    • Site-wide: 1,041
  • Since beginning of last month:
    • Site-wide: 892

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide